Navigation Links
AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
Date:9/26/2011

IRVINE, Calif., Sept. 26, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, has made a copy of the presentation shown at the Rodman and Renshaw 13th Annual Healthcare Conference available on the Company website at: www.AtheroNova.com .

"We were very pleased with the reception we received following our first major conference presentation at the Rodman & Renshaw Healthcare Conference last week in New York," said Thomas W. Gardner, CEO of AtheroNova. "Positive response keeps coming in including a column in Seeking Alpha that described AtheroNova as one 'of the new companies,' that 'stood out,' at the conference. As we continue to advance our drug development program, we will also continue to enhance our communications with the investors and look forward to meeting with investors at future conferences."

The PowerPoint presentation from the conference is available on our website at www.AtheroNova.com and the Seeking Alpha column is available by clicking here.

Highlights of the presentation include:

  • $4.1 Million Maxwell Agreement for Phase I and Phase II Clinical trial funding (details below)
  • $41+ Billion in Annual US Drug Costs related to Atherosclerosis
  • Anticipated Near Term Milestones
  • Potential Market Size
  • Pre-clinical Studies
  • Drug Development Timeline
  • Research
  • Management/Scientific Advisory Board

  • The presentation also contains an update on the Mechanisms of Action (MOA)  properties of AtheroNova's AHRO-001 lead compound for the regression of atherosclerotic plaque, which include:

  • Decreasing cholesterol absorption
  • Decreasing plasma LDL cholesterol levels
  • Upregulating ABCA1/ABCG1 gene expression
  • Increasing the efficiency of HDL
  • Potential Plaque Reversibility
  • Stimulate Reverse Cholesterol Transport
  • Atheroprotective Effects

  • As well as updates on the Company's innovative Drug Development Pipeline which currently encompasses:AHRO-001

    Enteric coated tabletAHRO-002

    Enteric stepwise therapeuticAHRO-003

    Statin combinationAHRO-200

    Dialysate additiveAHRO-100

    Obesity treatmentAHRO-010

    Dissolution of lipomasAHRO-300

    Localized transdermal fat dissolution Information is also presented on the Company's recently announced agreement with the Maxwell Biotech Group ("Maxwell") to license commercialization rights for AtheroNova's AHRO-001 lead atherosclerotic plaque regression compound. Maxwell, with funding provided by the Maxwell Biotech Venture Fund, Russia's premier biotech venture capital firm, will become equity investors in AtheroNova and commit to fund Phase I and Phase II human clinical studies in Russia. In return for this investment, AtheroNova will issue up to $4.1 million in common stock and grant to Maxwell an exclusive license to develop and commercialize AHRO-001 in the territory encompassing the Russian Federation, Belorussia, Ukraine, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Moldova, Azerbaijan and Armenia

    About AtheroNovaAtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits.  The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.  www.AtheroNova.com

    Forward-Looking StatementsExcept for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the Company's pipeline, milestones, future filings and trials, markets, mechanisms of action, licensing agreements and equity investment as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


    '/>"/>

    SOURCE AtheroNova Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
    2. Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference
    3. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
    4. ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
    5. Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
    6. Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai
    7. ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai
    8. NeoStem to Present at Rodman & Renshaws 12th Annual Healthcare Conference
    9. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
    10. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
    11. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... New York, NY (PRWEB) , ... ... ... International (BPI), a business-to-business publication dedicated to delivering cutting-edge information focused on ... GE Healthcare Life Sciences to become a premier sponsor of the 2016 ...
    (Date:2/11/2016)... WASHINGTON , Feb. 11, 2016   BioInformant ... strategic report, "Stem Cell Research Products, Opportunities, Tools, and ... 2020. ... specialize in the stem cell industry, BioInformant has more ... of the stem cell market, by stem cell type. ...
    (Date:2/11/2016)... ... , ... Global Stem Cells Group, has announced ... new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, focusing ... The new GSCG clinic is headed by four prominent Ecuadorian physicians, including Pablo ...
    (Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
    Breaking Biology Technology:
    (Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
    (Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
    (Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
    Breaking Biology News(10 mins):